[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349931-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349931-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","rapid-decentralized-prostate-cancer-risk-stratification-by-portable-liquid-biopsy-analysis-within-a-clinical-biosensor-validation-framework","Rapid Decentralized Prostate Cancer Risk Stratification by Portable Liquid Biopsy Analysis within a Clinical Biosensor Validation Framework","","Clinical liquid biopsy specimens such as blood or urine provide minimally invasive molecular information, but most profiling still relies on centralized laboratory testing that increases cost, delays results, and adds patient stress. Purposeful clinical validation of emerging liquid biopsy technologies is also limited. This work presents AVATAR, a portable electrochemical biosensor platform for rapid, accurate decentralized prostate cancer urinary circulating RNA biomarker profiling. Independent training and validation cohorts show improved risk stratification within 55 minutes, with additional longitudinal follow-up demonstrating biomarker correlations with matched tissue transcriptomic sequencing.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/rapid-decentralized-prostate-cancer-risk-stratification-by-portable-liquid-biopsy-analysis-within-a-clinical-biosensor-validation-framework/349931/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/rapid-decentralized-prostate-cancer-risk-stratification-by-portable-liquid-biopsy-analysis-within-a-clinical-biosensor-validation-framework/349931.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address in prostate cancer liquid biopsy testing?","Question",{"text":63,"@type":64},"Current molecular profiling is largely limited to centralized laboratory workflows, which increases costs, delays turnaround time, and can heighten patient anxiety. The study also notes that rigorous clinical validation studies for emerging technologies are scarce.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is AVATAR and what technology enables it?",{"text":68,"@type":64},"AVATAR is a biosensor approach that integrates accelerated isothermal assay chemistry with wireless mobile operation and a portable electrochemical readout platform. A custom mobile app supports operation control and result display after specimen collection.",{"name":70,"@type":61,"acceptedAnswer":71},"How well does AVATAR perform for prostate cancer risk stratification?",{"text":72,"@type":64},"Using independent training (n = 124) and validation (n = 114) urinary specimen cohorts, AVATAR achieves strong risk stratification performance, with AUC values of 0.88 and 0.86, respectively, within 55 minutes of assay time.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349931,1791165971,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":109,"preview_page_count":33,"preview_urls":145},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Advanced Science    \n[www.advancedscience.com](www.advancedscience.com)  \n RESEARCH ARTICLE   \nRapid Decentralized Prostate Cancer Risk Stratification by Portable Liquid Biopsy Analysis within a Clinical Biosensor Validation Framework  \nKevin M. Koo1, 2, 3  John W. Yaxley1, 5  Scott A. Tomlins8, 9  \n Grant Phillips2  Sriganesh Srihari4  Áine Farrell1  Binny Jaradi2  Kira J. Fitzpatrick2 Hemamali Samaratunga1, 6, 7  Paul N. Mainwaring2  Ke-lin Ru3  Darren J. Korbie3   \nMatthew J. Roberts1, 5, 7  Robert A. Gardiner1, 5, 10  Matt Trau3, 11   \n1The University of Queensland Centre for Clinical Research (UQCCR), Brisbane, QLD, Australia  2XING Applied Research & Assay Development (XARAD) Division, XING Technologies Pty Ltd, Brisbane, QLD, Australia  3 Centre for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD, Australia  4 QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Translational and Human Immunology Laboratory, Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia   \n5 Department of Urology, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia  6Aquesta Specialized Uropathology, Brisbane, QLD, Australia   \n7 Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, QLD, Australia  8 Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA  9 Strata Oncology, Ann Arbor, MI, USA  10 Edith Cowan University, Perth, WA, Australia  11 School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia  \nCorrespondence: Kevin M. Koo ([maisheng.koo@uqconnect.edu.au](maisheng.koo@uqconnect.edu.au))  Matthew J. Roberts (m.roberts2@uq.edu.au)  Robert A. Gardiner ([f.gardiner@uq.edu.au](f.gardiner@uq.edu.au))  Matt Trau (m.trau@uq.edu.au)  \nReceived: 1 July 2025  Revised: 23 November 2025  Accepted: 8 December 2025  \nKeywords: prostate cancer | liquid biopsy | clinical validation | biomarkers | biosensor  \nABSTRACT  \nClinical liquid biopsy (e.g., blood or urine) specimens, as a minimally invasive source of crucial molecular information, continue to grow in importance for efficacious targeted cancer treatment. Yet, current molecular profiling technologies are still confined to centralized laboratory testing, which escalates testing costs, result turnaround time, and patient anxiety. Crucially, there is also a scarcity of purposeful clinical validation studies to rigorously evaluate emerging liquid biopsy technologies from research settings to facilitate clinical translation. Here, we report liquid biopsy biosensor advancements in achieving rapid, accurate, and decentralized molecular profiling of a clinically accredited prostate cancer (PCa) urinary circulating RNA biomarker panel. This biosensor approach, termed ‘Accelerated non-inVasive bioAnalyte testing And Reporting’ (AVATAR), integrates accelerated isothermal assay chemistry and wireless mobile operation capabilities onto a portable electrochemical readout platform. AVATAR enables easy operational control and result display with a custom mobile app following liquid biopsy specimen collection. Using independent training (n = 124) and validation (n = 114) PCa clinical urinary specimen cohorts, we showed AVATAR achieved superior PCa risk stratification to current clinical PCa testing with area-under-curve values of 0.88 (95% confidence interval: 0.84−0.92) and 0.86 (95% confidence interval: 0.83−0.89), respectively within 55 min of assay time. To further accelerate AVATAR for using PCa liquid biopsies as a surrogate for invasive tissue sampling, we designed a tailored multi-year PCa follow-up study with individual patient liquid biopsy specimens showing strong molecular biomarker correlation with comprehensive transcriptomic sequencing of matched tissue specimens (n = 39). By creating thisbespoke biosensor technology clinical translation","cbCaiv1tk5npWwCp","https://ap.wps.com/l/cbCaiv1tk5npWwCp","pdf",3166120,16,"English","# Abstract\n## Rapid decentralized risk stratification using AVATAR\n## Training, validation, and assay performance\n## Longitudinal follow-up and correlation with tissue sequencing\n# Introduction\n## Minimally invasive liquid biopsies vs tissue biopsy limitations\n## Prostate cancer diagnosis and the role of PSA testing","[{\"question\":\"What problem does the study address in prostate cancer liquid biopsy testing?\",\"answer\":\"Current molecular profiling is largely limited to centralized laboratory workflows, which increases costs, delays turnaround time, and can heighten patient anxiety. The study also notes that rigorous clinical validation studies for emerging technologies are scarce.\"},{\"question\":\"What is AVATAR and what technology enables it?\",\"answer\":\"AVATAR is a biosensor approach that integrates accelerated isothermal assay chemistry with wireless mobile operation and a portable electrochemical readout platform. A custom mobile app supports operation control and result display after specimen collection.\"},{\"question\":\"How well does AVATAR perform for prostate cancer risk stratification?\",\"answer\":\"Using independent training (n = 124) and validation (n = 114) urinary specimen cohorts, AVATAR achieves strong risk stratification performance, with AUC values of 0.88 and 0.86, respectively, within 55 minutes of assay time.\"}]","Rapid Decentralized Prostate Cancer Risk Stratification by Portable Liquid Biopsy Analysis within a Clinical Biosensor Validation Framework | PDF",1790086306,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2324c0ae009b65db59bd55ea953fdfb8.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/89a2025f5398b6ad6e7342c090539830.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1650b01199af5b09c7089efeb62531a1.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/842bff50565e17c78dbdc27f5277274a.webp",980,1287]